Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health ...
Akebia Therapeutics gets EMA panel support for Xoanacyl to treat high phosphate & iron deficiency in CKD. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback